Chordoma: Frequently Asked Questions
1. What are the early symptoms of chordoma?
Chordoma symptoms depend on the tumor's location.Skull base chordomas manifest as double vision, headaches, and chronic sinus issues.
2. Is chordoma a malignant tumor?
Chordoma is a malignant tumor characterized by local invasiveness, capable of invading surrounding bone and soft tissue.Although slow-growing, it is difficult to excise completely and has a high recurrence rate.
3. What are the surgical treatment options for chordoma?
Chordoma surgery aims for wide resection, removing the tumor and affected tissues as thoroughly as possible.Skull base chordomas require a multidisciplinary team approach and are resected via transcranial or transnasal routes.
4. What is minimally invasive treatment for chordoma?
The endoscopic transnasal approach is a key minimally invasive method for treating skull base chordomas, allowing tumor resection without craniotomy.Stereotactic radiotherapy is suitable for small residual or recurrent lesions after surgery.
5. Why is adjuvant radiotherapy needed for chordoma?
Since chordomas are difficult to excise completely, postoperative adjuvant radiotherapy can reduce the rate of local recurrence.Proton therapy and heavy-ion therapy allow for the precise delivery of high-dose radiation while protecting surrounding vital tissues.
6. What progress has been made in targeted therapy for chordoma?
Imatinib has shown some efficacy in a subset of chordoma patients.EGFR inhibitors are also being investigated.Targeted therapy is primarily used for patients with unresectable, recurrent, or metastatic disease.
7. How is follow-up conducted after chordoma treatment?
Chordomas require lifelong periodic follow-up, with annual MRI or CT scans to monitor for recurrence.Attention should be paid to localized pain and changes in neurological function.For sacrococcygeal chordomas, bowel and bladder function must be monitored.
